Antimicrobial and synergistic activity of thiazoline derivatives in combination with conventional antibiotics against multidrug resistant Staphylococcus aureus isolated from abscess drainage samples.

Journal: Pakistan journal of pharmaceutical sciences
PMID:

Abstract

Emergence and spread of multidrug resistant (MDR) Staphylococcus aureus strains is becoming major challenge in treatment of soft tissue infections. This study aimed to explore antimicrobial and synergistic antimicrobial potential of three commercially available thiazoline derivatives (2-amino-2-thiazoline, 2-thiazoline-2-thiol and 2-acetyl-2-thiazoline) against MDR Staphylococcus aureus strains isolated from abscess drainage samples (n=20). MDR Staphylococcus aureus isolates were identified by Kirby-Bauer disk diffusion assay and were further subjected to molecular identification by 16srRNA amplification and DNA sequencing. Minimum Inhibitory Concentration (MIC) values of test compounds and antibiotics (0.25-512μg/mL) were measured and subsequently, synergism assay was performed to calculate Fractional Inhibitory Concentration (FIC) index. Out of twenty Staphylococcus aureus isolates, sixteen (80%) were found to be MDR whereas four (20%) were Non-MDR. Moxifloxacin and vancomycine were found most effective antibiotics, inhibiting 100% (n=20) and 95% (n=19) strains respectively. Antimicrobial activity of 2-amino-2-thiazoline (MIC: 32μg/mL), 2-thiazoline-2-thiol (MIC: 64μg/mL) and 2-acetyl-2-thiazoline (MIC: 32μg/mL) was found significant against all ten tested MDR strains. Synergistic combinations of thiazoline derivatives with test antibiotics reduced MIC values significantly. Therefore, combination of tested thiazoline derivatives with antibiotics could be used as alternative therapeutic approach to treat soft tissue infections caused by MDR Staphylococcus aureus after further pre-clinical and clinical studies.

Authors

  • Muhammad Amir Khan
    Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan / Department of Pharmacology, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
  • Shaukat Ali
    Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Sumbul Shamim
    Department of Pharmacology, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
  • Nazia Ahmed
    Dow Research Institute of Biotechnology and Biosciences, Dow University of Health Sciences, Karachi, Pakistan.
  • Mushtaq Hussain
    Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Saba Farooq
    National Institute of Virology, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
  • Sadaf Khan
    Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.